Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$19.56 +0.4%	$18.23	$16.10 ▼ $41.94	$2.45B	0.67	2.37 million shs	467,097 shs
BHC Bausch Health Cos	$6.36 +0.7%	$5.60	$3.96 ▼ $9.85	$2.35B	0.41	2.52 million shs	539,913 shs
GMTX Gemini Therapeutics	$57.77 0.0%	$51.05	$1.16 ▼ $14.10	$2.50B	-0.12	189,291 shs	672,319 shs
SANA Sana Biotechnology	$4.60 -0.8%	$2.78	$1.26 ▼ $7.30	$1.02B	1.86	3.93 million shs	4.36 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	+0.15%	+10.06%	+7.99%	-48.74%
BHC Bausch Health Cos	0.00%	-1.87%	+2.27%	+33.69%	-16.97%
GMTX Gemini Therapeutics	0.00%	+1.51%	+15.33%	+37.01%	+27.25%
SANA Sana Biotechnology	0.00%	+10.77%	+77.39%	+191.19%	-20.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.3324 of 5 stars	4.3	0.0	0.0	4.4	2.6	2.5	0.6
BHC Bausch Health Cos	3.4863 of 5 stars	1.9	4.0	0.0	4.0	0.6	3.3	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	3.467 of 5 stars	3.5	3.0	0.0	0.0	3.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.00	104.55% Upside
BHC Bausch Health Cos	1.83	Reduce	$7.30	14.87% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
SANA Sana Biotechnology	3.00	Buy	$9.17	99.49% Upside

Current Analyst Ratings Breakdown

Latest SANA, BHC, GMTX, and APLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/8/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $18.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	3.15	N/A	N/A	$1.84 per share	10.63
BHC Bausch Health Cos	$9.63B	0.24	$7.75 per share	0.82	($0.89) per share	-7.14
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.36	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)

Latest SANA, BHC, GMTX, and APLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.9320	N/A	N/A	N/A	$2.47 billion	N/A
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
BHC Bausch Health Cos	N/A	1.35	0.97
GMTX Gemini Therapeutics	N/A	71.49	71.49
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
BHC Bausch Health Cos	78.65%
GMTX Gemini Therapeutics	75.42%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.80%
BHC Bausch Health Cos	8.12%
GMTX Gemini Therapeutics	12.90%
SANA Sana Biotechnology	31.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.14 million	Optionable
BHC Bausch Health Cos	20,700	370.09 million	340.04 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
SANA Sana Biotechnology	380	225.48 million	155.35 million	Optionable

SANA, BHC, GMTX, and APLS Headlines

Recent News About These Companies

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Sana Biotechnology, Inc. (SANA) Secures an Overweight Rating from Morgan Stanley

July 11, 2025 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Up - Here's Why

July 9, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 14.1% - Still a Buy?

July 8, 2025 | marketbeat.com

Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting

July 4, 2025 | msn.com

Sana Biotechnology (NASDAQ:SANA) Coverage Initiated by Analysts at Morgan Stanley

July 3, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.6% - What's Next?

July 2, 2025 | marketbeat.com

Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results

June 29, 2025 | insidermonkey.com

Sana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.com

June 26, 2025 | investing.com

Sana Biotechnology (SANA) Receives a Buy from Citizens JMP

June 26, 2025 | theglobeandmail.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 4.5% - Time to Sell?

June 25, 2025 | marketbeat.com

BofA Remains Bullish on Sana Biotechnology (SANA)

June 24, 2025 | insidermonkey.com

Sana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP Securities

June 24, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 17.2% - Should You Buy?

June 23, 2025 | marketbeat.com

Sana Biotechnology stock soars after positive diabetes treatment results

June 23, 2025 | investing.com

Two Biotech Stocks Poised For Big Moves On Monday

June 23, 2025 | benzinga.com

Sana Biotechnology Shares Climb on Positive Diabetes Study Results

June 23, 2025 | marketwatch.com

Sana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 Diabetes

June 23, 2025 | quiverquant.comQ

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

June 23, 2025 | globenewswire.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from Analysts

June 22, 2025 | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, BHC, GMTX, and APLS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$19.56 +0.09 (+0.44%)

As of 02:43 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Bausch Health Cos NYSE:BHC

$6.36 +0.05 (+0.71%)

As of 02:43 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Gemini Therapeutics NASDAQ:GMTX

$57.77 -0.02 (-0.03%)

As of 07/18/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$4.60 -0.04 (-0.76%)

As of 02:43 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time